Mohammad Hossein Jamshidi - Department of medical physics, Faculty of medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mansour Zabihzadeh - Department of medical physics, Faculty of medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Most women who are newly diagnosed with early-stage breast cancer have a choice of: breast-conserving surgery (such as lumpectomy), a mastectomy, radiationtherapy and systemic treatments. As an alternative treatment method for patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has been introduced. A novel brachytherapy of (APBI) has been developed in recent years. This technique uses the MammoSite brachytherapy system as a sole radiation treatment for patient with early stage breast cancer following lympectomy. It consists of a small ballon connected to a catheter wich has an inflation channel and a catheter frompassage of a high dose rate brachyterapy source (Ir-192). The device is placed in the lympectomy cavity during or following breast surgery. The treatment with the MammoSite device is generally is 34 Gy delivered in 10 fractions (3.4 Gy / fraction twice daily) at 1 cm from the ballon surface with minimum of 6 hours betwewn fraction on the same day. The endpoint of the MammoSite treatment technique as with any other radiotherapy modality is to achieve high tumour control probability and minimal normal tissue complications. Existing clinical findings have demonstrated highly acceptable outcomes with the MammoSite brachytherapy (MSB) applicator regarding tumour control, acute complications and cosmetic results. Treatment efficacy, cosmesis, and toxicity 3 years after treatment with APBI using the MammoSite device are good and similar to those reported with other forms of APBI with similar follow-up. In conclusion, the MammoSite is a suitable technique for APBI. It offers good outcomes and shorter treatment schedules.

MammoSite, Brachytherapy, breast cancer